Bonnie Gillis

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

The combination of temsirolimus plus bevacizumab was not superior to interferon plus bevacizumab as first-line therapy for patients with clear cell metastatic renal cell carcinoma.

Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.

Amrubicin improved response rates, improved progression- free survival (PFS), and achieved enhanced symptom control with acceptable toxicity compared with topotecan.

Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia